USP21 regulates Hippo pathway activity by mediating MARK protein turnover

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

USP21 regulates Hippo pathway activity by mediating MARK protein turnover. / Nguyen, Thanh Hung; Kugler, Jan-Michael; Loya, Anand Chainsukh; Cohen, Stephen Michael.

I: OncoTarget, Bind 8, 2017, s. 64095-64105.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Nguyen, TH, Kugler, J-M, Loya, AC & Cohen, SM 2017, 'USP21 regulates Hippo pathway activity by mediating MARK protein turnover', OncoTarget, bind 8, s. 64095-64105. https://doi.org/10.18632/oncotarget.19322

APA

Nguyen, T. H., Kugler, J-M., Loya, A. C., & Cohen, S. M. (2017). USP21 regulates Hippo pathway activity by mediating MARK protein turnover. OncoTarget, 8, 64095-64105. https://doi.org/10.18632/oncotarget.19322

Vancouver

Nguyen TH, Kugler J-M, Loya AC, Cohen SM. USP21 regulates Hippo pathway activity by mediating MARK protein turnover. OncoTarget. 2017;8:64095-64105. https://doi.org/10.18632/oncotarget.19322

Author

Nguyen, Thanh Hung ; Kugler, Jan-Michael ; Loya, Anand Chainsukh ; Cohen, Stephen Michael. / USP21 regulates Hippo pathway activity by mediating MARK protein turnover. I: OncoTarget. 2017 ; Bind 8. s. 64095-64105.

Bibtex

@article{6900c6e2c77847148e98b772f6b0d515,
title = "USP21 regulates Hippo pathway activity by mediating MARK protein turnover",
abstract = "The Hippo pathway, which acts to repress the activity of YAP and TAZ trancriptional co-activators, serve as a barrier for oncogenic transformation. Unlike other oncoproteins, YAP and TAZ are rarely activated by mutations or amplified in cancer. However, elevated YAP/TAZ activity is frequently observed in cancer and often correlates with worse survival. The activity and stability of Hippo pathway components, including YAP/TAZ, AMOT and LATS1/2, are regulated by ubiquitin-mediated protein degradation. Aberrant expression of ubiquitin ligase complexes that regulate the turnover of Hippo components and deubiquitylating enzymes that counteract these ubiquitin ligases have been implicated in human cancer. Here we identify the USP21 deubiquitylating enzyme as a novel regulator of Hippo pathway activity. We provide evidence that USP21 regulates YAP/TAZ activity by controlling the stability of MARK kinases, which promote Hippo signaling. Low expression of USP21 in early stage renal clear cell carcinoma suggests that USP21 may be a useful biomarker.",
author = "Nguyen, {Thanh Hung} and Jan-Michael Kugler and Loya, {Anand Chainsukh} and Cohen, {Stephen Michael}",
year = "2017",
doi = "10.18632/oncotarget.19322",
language = "English",
volume = "8",
pages = "64095--64105",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",

}

RIS

TY - JOUR

T1 - USP21 regulates Hippo pathway activity by mediating MARK protein turnover

AU - Nguyen, Thanh Hung

AU - Kugler, Jan-Michael

AU - Loya, Anand Chainsukh

AU - Cohen, Stephen Michael

PY - 2017

Y1 - 2017

N2 - The Hippo pathway, which acts to repress the activity of YAP and TAZ trancriptional co-activators, serve as a barrier for oncogenic transformation. Unlike other oncoproteins, YAP and TAZ are rarely activated by mutations or amplified in cancer. However, elevated YAP/TAZ activity is frequently observed in cancer and often correlates with worse survival. The activity and stability of Hippo pathway components, including YAP/TAZ, AMOT and LATS1/2, are regulated by ubiquitin-mediated protein degradation. Aberrant expression of ubiquitin ligase complexes that regulate the turnover of Hippo components and deubiquitylating enzymes that counteract these ubiquitin ligases have been implicated in human cancer. Here we identify the USP21 deubiquitylating enzyme as a novel regulator of Hippo pathway activity. We provide evidence that USP21 regulates YAP/TAZ activity by controlling the stability of MARK kinases, which promote Hippo signaling. Low expression of USP21 in early stage renal clear cell carcinoma suggests that USP21 may be a useful biomarker.

AB - The Hippo pathway, which acts to repress the activity of YAP and TAZ trancriptional co-activators, serve as a barrier for oncogenic transformation. Unlike other oncoproteins, YAP and TAZ are rarely activated by mutations or amplified in cancer. However, elevated YAP/TAZ activity is frequently observed in cancer and often correlates with worse survival. The activity and stability of Hippo pathway components, including YAP/TAZ, AMOT and LATS1/2, are regulated by ubiquitin-mediated protein degradation. Aberrant expression of ubiquitin ligase complexes that regulate the turnover of Hippo components and deubiquitylating enzymes that counteract these ubiquitin ligases have been implicated in human cancer. Here we identify the USP21 deubiquitylating enzyme as a novel regulator of Hippo pathway activity. We provide evidence that USP21 regulates YAP/TAZ activity by controlling the stability of MARK kinases, which promote Hippo signaling. Low expression of USP21 in early stage renal clear cell carcinoma suggests that USP21 may be a useful biomarker.

U2 - 10.18632/oncotarget.19322

DO - 10.18632/oncotarget.19322

M3 - Journal article

C2 - 28969054

VL - 8

SP - 64095

EP - 64105

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -

ID: 181141195